CureVac raises €28 million to fund clinical development of mRNA vaccines
This article was originally published in Scrip
Executive Summary
CureVac, which is developing mRNA-based vaccines, has raised around €28 million in a series C financing round from its major shareholder, Dievini Hopp BioTech.